Vaxxinity | Evaluate

December 02, 2021

Novartis gets in on alpha-synuclein

September 03, 2021

No let-up in Covid-19 vaccine trials

A project from SK Bioscience and Glaxo started phase 3 this week, but it is far from the only late-stage candidate.

July 28, 2021

AC Immune backs alpha-synuclein despite recent setbacks

The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.